We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: A systematic review and meta-analysis.
- Authors
Hamidi, Oksana; Young, William F.; Gruber, Lucinda; Smestad, John; Yan, Qi; Ponce, Oscar J.; Prokop, Larry; Murad, Mohammad Hassan; Bancos, Irina
- Abstract
Objective The outcomes of patients with metastatic phaeochromocytoma (PHEO) and paraganglioma (PGL) are unclear. We performed a systematic review and meta-analysis of baseline characteristics and mortality rates of patients with metastatic PHEO and PGL (PPGL). Design Ovid MEDLINE In-Process & Other Non-Indexed Citations, Ovid MEDLINE, Ovid EMBASE, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, Scopus, Web of Science, and references of key articles were searched from inception to 2016. Patients Studies comprised ≥20 patients with metastatic PPGL and reported baseline characteristics and follow-up data. Measurements Reviewers extracted standardized data and assessed risk of bias using a modified Newcastle-Ottawa tool. Random-effects meta-analysis was used to pool event rates across studies. Results Twenty retrospective noncomparative studies reported on 1338 patients with metastatic PHEO (685/1296, 52.9%) and PGL (611/1296, 47.1%), diagnosed at a mean age of 43.9 ± 5.2 years. Mean follow-up was 6.3 ± 3.2 years. Of 532 patients with reported data, 40.4% had synchronous metastases. Five-year (7 studies, n = 738) and 10-year (2 studies, n = 55) mortality rates for patients with metastatic PPGL were 37% (95% CI, 24%-51%) and 29% (95% CI, 17%-42%), respectively. Higher mortality was associated with male sex (RR 1.50; 95% CI, 1.11-2.02) and synchronous metastases (RR 2.43; 95% CI, 1.01-5.85). Conclusions Available low-quality evidence from heterogeneous studies suggests low mortality rates of patients with metastatic PPGL. Male sex and synchronous metastases correlated with increased mortality. The outcomes of patients with metastatic PPGL have been inadequately assessed, indicating the need for carefully planned prospective studies.
- Subjects
PHEOCHROMOCYTOMA; METASTASIS; PARAGANGLIOMA; NEUROENDOCRINE tumors; CANCER-related mortality; ADRENAL tumors
- Publication
Clinical Endocrinology, 2017, Vol 87, Issue 5, p440
- ISSN
0300-0664
- Publication type
Article
- DOI
10.1111/cen.13434